Home    Back

Anastrozole    (DrugBank: Anastrozole)

3 diseases
IDDisease name (Link within this page)Number of trials
78Hypopituitarism2
86Pulmonary arterial hypertension2
193Prader-Willi syndrome2

78. Hypopituitarism    [ 462 clinical trials,   346 drugs,   (DrugBank: 45 drugs),   41 drug target genes,   80 drug target pathways]
Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 462 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00133354
(ClinicalTrials.gov)		November 200119/8/2005Arimidex Multicenter Trial in Growth Hormone (GH) Deficient BoysDouble-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) DeficiencyHypopituitarismDrug: Arimidex (Anastrozole);Drug: Placebo;Drug: Growth HormoneNemours Children's ClinicAstraZeneca;Genentech, Inc.;EMD SeronoCompleted11 Years18 YearsMale53Phase 2;Phase 3United States
2EUCTR2012-001183-30-Outside-EU/EEA
(EUCTR)		09/03/2012The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay bone fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone.Double-blind trial investigating the safety and efficacy of the inhibitor anastrozole (arimidex) in delaying epiphyseal fusion and increasing height potential of adolescent males with growth hormone (GH) deficiency. hypopituitarism
MedDRA version: 14.1;Level: PT;Classification code 10021067;Term: Hypopituitarism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Trade Name: Arimidex
Product Name: Arimidex
Product Code: ZD1033
INN or Proposed INN: anastrozole
Other descriptive name: ANASTROZOLE		Nemours Children's ClinicNULLNAFemale: no
Male: yes		53United States

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,083 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03229499
(ClinicalTrials.gov)		December 7, 201718/7/2017Pulmonary Hypertension and Anastrozole TrialPulmonary Hypertension and Anastrozole Trial (PHANTOM)Pulmonary Arterial HypertensionDrug: Anastrozole;Drug: Placebo Oral TabletUniversity of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI);Johns Hopkins University;University of Colorado, Denver;Rhode Island Hospital;Stanford University;Vanderbilt University;Washington University School of MedicineRecruiting18 YearsN/AAll84Phase 2United States
2NCT01545336
(ClinicalTrials.gov)		October 201229/2/2012Anastrozole in Patients With Pulmonary Arterial HypertensionA Double-blind, Placebo-controlled Phase II Study of Anastrozole in Patients With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Anastrozole;Drug: PlaceboUniversity of PennsylvaniaNULLCompleted18 YearsN/AAll18Phase 2United States

193. Prader-Willi syndrome    [ 95 clinical trials,   104 drugs,   (DrugBank: 27 drugs),   50 drug target genes,   63 drug target pathways]
Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 95 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1ChiCTR1900027464
2019-12-012019-11-14Efficacy and safety of anastrozole combined with growth hormone in the treatment of Prader Willi syndrome in boys of large bone ageEfficacy and safety of anastrozole combined with growth hormone in the treatment of Prader Willi syndrome in boys of large bone age Prader-Willi syndromecontrol group:Single rhGH therapy;observation group:Anastrazole combined with growth hormone therapy;Children's Hospital of Zhejiang University School of MedicineNULLPendingMalecontrol group:20;observation group:20;Phase 4China
2NCT01520467
(ClinicalTrials.gov)		April 201225/1/2012Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi SyndromeEfficacy and Tolerance of Treatment With an Aromatase Inhibitor (Anastrozole) to Limit the Progression of Bone Maturation Related to Pathological Adrenarche in Children With Silver-Russell or Prader-Willi SyndromeSilver Russell Syndrome;Prader-Willi SyndromeDrug: Anastrozole;Drug: PlaceboAssistance Publique - Hôpitaux de ParisNULLActive, not recruiting5 Years12 YearsBoth27N/AFrance

Back to top